Actinogen Medical targets Alzheimer’s treatment gap in projected $20BN market
Last updated: 17:43 18 Nov 2026 EST, First published: 12:22 05 Aug 2026 EDT
Snapshot
- Actinogen Medical identifies 30% slowing of Alzheimer's progression in older patients
- Actinogen Medical targets Alzheimer’s treatment gap in projected $20BN market
- Actinogen Medical with Proactive at ASX Small and Mid Cap Conference
About the company
Actinogen Medical is a biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol.
The company is currently developing its lead compound, Xanamem®, as a revolutionary new therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact.
How it is doing
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has reported a 30% slowing of Alzheimer's disease progression among patients aged over 75 in its pivotal XanaMIA clinical trial, although its experimental treatment Xanamem failed to achieve statistical significance across the overall study population.
The Sydney-based biotechnology company released topline results from the 36-week trial involving 247 patients with mild to moderate Alzheimer's disease, identifying encouraging treatment responses in older participants.
Among patients over 75, 40% receiving Xanamem showed no disease progression compared with 22% receiving a placebo, a statistically significant difference.
The company also reported a 30% slowing of disease progression in this age group, although that measure did not reach statistical significance.
Australia’s small-cap stocks remained under pressure on Wednesday, with the S&P/ASX Small Ordinaries Index (XSO) falling 46.60 points, or 1.48%, to close at 3,097.40.
The index has now shed 224.80 points, or 6.77%, over the past five trading sessions, reflecting continued weakness across the smaller end of the Australian sharemarket.
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has received a $10.8 million research and development tax incentive rebate from the Australian Taxation Office (ATO) for the 2026 financial year, strengthening its cash position ahead of pivotal Xanamem Alzheimer’s disease trial results expected in mid-November.
The rebate, which includes interest, totalled $10,838,793.
Insight: Actinogen Medical targets Alzheimer’s treatment gap in projected $20BN market
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) is approaching a defining clinical milestone as it advances Xanamem, a once-daily oral therapy designed to slow Alzheimer’s disease by controlling elevated cortisol in the brain.
The company’s fully enrolled XanaMIA Phase 2b/3 trial is expected to report topline results in November 2026, providing the most important test yet of whether Xanamem can deliver a meaningful benefit in patients with mild-to-moderate Alzheimer’s disease.
What management says
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) CEO Steven Gourlay is with Proactive’s Jonathan Jackson live from the ASX Small and Mid Cap Conference in March 2024. In a nutshell, the biotechnology company is developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. According to Actinogen, there is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long term cognitive health.
Sewell says the company is developing its lead compound, Xanamem®, as a new therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome and other neurological diseases where reducing cortisol inside brain cells could have a positive impact.